Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
Studies were conducted to investigate mutation pathways among subtypes A, B, and C of human immunodeficiency virus type 1 (HIV-1) during resistance selection with nonnucleoside reverse transcriptase inhibitors (NNRTIs) in cell culture under low-multiplicity of infection (MOI) conditions. The results showed that distinct pathways were selected by different virus subtypes under increasing selective pressure of NNRTIs. F227C and Y181C were the major mutations selected by MK-4965 in subtype A and C viruses during resistance selection. With efavirenz (EFV), F227C and V106M were the major mutations responsible for viral breakthrough in subtype A viruses, whereas a single pathway (G190A/V106M) accounted for mutation development in subtype C viruses. Y181C was the dominant mutation in the resistance selection with etravirine (ETV) in subtype A, and E138K/H221Y were the mutations detected in the breakthrough viruses from subtype C viruses with ETV. In subtype B viruses, on the other hand, known NNRTI-associated mutations (e.g., Y181C, P236L, L100I, V179D, and K103N) were selected by the NNRTIs. The susceptibility of the subtype A and B mutant viruses to NNRTIs was determined in order to gain insight into the potential mechanisms of mutation development. Collectively, these results suggest that minor differences may exist in conformation of the residues within the NNRTI binding pocket (NNRTIBP) of reverse transcriptase (RT) among the three subtypes of viruses. Thus, the interactions between NNRTIs and the residues in the NNRTIBPs of different subtypes may not be identical, leading to distinct mutation pathways during resistance selection in cell culture.
Lai
Ming-Tain
MT
Department of Antiviral Research, Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA 19486, USA. mingtain_lai@merck.com
Lu
Meiqing
M
Felock
Peter J
PJ
Hrin
Renee C
RC
Wang
Ying-Jie
YJ
Yan
Youwei
Y
Munshi
Sanjeev
S
McGaughey
Georgia B
GB
Tynebor
Robert M
RM
Tucker
Thomas J
TJ
Williams
Theresa M
TM
Grobler
Jay A
JA
Hazuda
Daria J
DJ
McKenna
Philip M
PM
Miller
Michael D
MD
D000480:Alkynes; D048588:Benzoxazines / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D003521:Cyclopropanes; D024882:Drug Resistance, Viral / Q000235:genetics*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D015394:Molecular Structure; D009154:Mutation; D009570:Nitriles; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology; D011724:Pyridazines / Q000737:chemistry / Q000494:pharmacology; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
C532853:3-(5-((6-amino-1H-pyrazolo(3,4-b)pyridine-3-yl)methoxy)-2-chlorophenoxy)-5-chlorobenzonitrile; D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D009570:Nitriles; D011720:Pyrazoles; D011724:Pyridazines; D011725:Pyridines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine; D054303:HIV Reverse Transcriptase; C098320:efavirenz
J Virol. 2005 Oct;79(20):12773-82
16188980
Science. 2000 Jan 28;287(5453):607-14
10649986
J Med Chem. 2008 Oct 23;51(20):6503-11
18826204
J Infect Dis. 2002 Sep 1;186(5):617-25
12195348
J Virol. 1997 Nov;71(11):8657-65
9343223
Virology. 2000 Sep 15;275(1):107-15
11017792
J Biol Chem. 2008 Aug 8;283(32):22222-32
18547911
AIDS. 2003 Jan 3;17(1):F1-5
12478089
J Mol Biol. 2001 Sep 28;312(4):795-805
11575933
Virus Genes. 2001;23(2):193-202
11724274
Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84
10952598
Lancet. 2007 Jul 7;370(9581):29-38
17617270
J Antimicrob Chemother. 2003 Feb;51(2):229-40
12562686
AIDS. 2007 Aug 20;21(13):1693-700
17690566
Pediatr Int. 2004 Apr;46(2):236-44
15056258
J Med Chem. 2005 Mar 24;48(6):1948-64
15771439
Antimicrob Agents Chemother. 2005 Sep;49(9):3930-2
16127074
Virus Res. 2008 Jun;134(1-2):104-23
18289713
AIDS. 2004 Apr 9;18(6):909-15
15060438
Antimicrob Agents Chemother. 2009 Jun;53(6):2424-31
19289522
Virology. 2006 Sep 15;353(1):184-92
16797050
Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5
8592986
Nat Med. 1998 Sep;4(9):1032-7
9734396
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11241-5
1722324
Mol Med. 1997 Jan;3(1):23-36
9132277
Nat Struct Biol. 1995 Apr;2(4):303-8
7540935
Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S48-52
18570754
J Virol. 2000 Sep;74(18):8390-401
10954539
Curr HIV/AIDS Rep. 2006 Jul;3(2):93-101
16608666
HIV Clin Trials. 2002 May-Jun;3(3):237-48
12032883
J Virol. 2001 Jun;75(11):4999-5008
11333879
PLoS Med. 2007 Dec;4(12):e335
18052601
Science. 2000 Jun 9;288(5472):1789-96
10846155
AIDS Rev. 2006 Apr-Jun;8(2):98-107
16848277
Nature. 1999 Feb 4;397(6718):436-41
9989410
Lancet. 2007 Jul 7;370(9581):39-48
17617271
Antivir Ther. 2002 Mar;7(1):31-5
12008785
J Virol Methods. 2010 May;165(2):230-7
20153375
J Antimicrob Chemother. 2008 Nov;62(5):909-13
18653487
Antimicrob Agents Chemother. 2010 Feb;54(2):718-27
19933797
J Virol. 2008 Apr;82(7):3261-70
18216099
PLoS Med. 2005 Apr;2(4):e112
15839752